Our findings revealed that the therapeutic effect of honokiol stems from its novel polypharmacological action on multiple ion channels and critical immune cells. By suppressing both early- (mast cell-driven) and late-phase (T cell-driven) allergic responses, this multitarget approach represents a new strategy for AR treatment that could overcome the limitations of current single-target therapies.